Pharmaceutical Industry Information Portal


All posts by tag


Veru shares up 38.5% YTD, but Q2 loss missed earnings expectations

Veru Inc. came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares...

Veru’s new drug COVID-19 reduces deaths by 55% among hospitalized patients in an interim analysis of a phase 3 study

Veru Inc., an oncology biopharmaceutical company, April 11th announced positive efficacy and safety results of Phase 3 COVID-19 clinical trial evaluating oral sabizabulin versus...

Expert Articles